Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
View original at finance.yahoo.comMerck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026? Merck & Co. MRK and Bristol Myers Squibb BMY are major global drugmakers with expansive, diversified portfolios…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Keytruda targets peak sales of $35 billion by 2028
80% confidencePhase III pipeline has almost tripled since 2021
80% confidenceZacks Consensus Estimate for MRK's 2026 EPS suggests decline of 38.75%
80% confidenceLegacy Portfolio sales expected to decline 12-16% in 2026
80% confidencePositioned to launch around 20 drugs over the next few years, with many having blockbuster potential
80% confidenceOperating expenses expected to decline in 2026, supporting margin expansion
80% confidenceZacks Consensus Estimate for BMY's 2026 EPS suggests increase of 0.33%
80% confidenceExpects headwind of approximately $2.5 billion from generic competition in 2026
80% confidenceZacks Consensus Estimate for MRK's 2026 sales implies year-over-year increase of 2.59%
80% confidenceAnnual revenue guidance of $46.0-$47.5 billion for 2026
80% confidenceTargeting $2 billion in annualized cost savings by the end of 2027
80% confidenceKeytruda will lose patient exclusivity in 2028
80% confidenceBMY's relatively attractive valuation and more favorable 2026 outlook position it as the more compelling investment choice versus MRK at present
80% confidenceExpects over $70 billion of potential non-risk-adjusted commercial opportunity for the current pipeline by the mid-2030s
80% confidenceAchieved approximately $1 billion in savings in 2025
80% confidenceZacks Consensus Estimate for BMY's 2026 sales implies year-over-year decrease of 2.32%
80% confidence